Latest News and Press Releases

Boehringer has licensed CDR111 from CDR-Life, an antibody-based trispecific M-gager® for autoimmune diseases.

Boehringer has licensed a small molecule program from Kyowa Kirin focused on developing potential treatments for autoimmune diseases.

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...

Dublin, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The "OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026" report has...

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into 2027.

Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK...

First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic...

Dublin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The "Tenosynovitis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset